Recent Advances in the Management of Adverse Events Associated with Lorlatinib

As a novel third-generation ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown excellent systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients who carry sensitizing ALK-activating mutations and progress on first- and second-generation TKIs. In comparison with other...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Dehua, Zhang, Jiwen, Yan, Ting, Chen, Shanshan, Li, Wei, Shangguan, Dangang, She, Zhihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492578/
https://www.ncbi.nlm.nih.gov/pubmed/37694103
http://dx.doi.org/10.2147/OTT.S426989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492578/
https://www.ncbi.nlm.nih.gov/pubmed/37694103
http://dx.doi.org/10.2147/OTT.S426989

Ejemplares similares